| Date Filed | Type | Description |
| 10/05/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 4.6% stake in SOLENO THERAPEUTICS, INC. |
| 09/29/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 7.3% stake in CHIMERIX, INC. |
| 08/25/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in TAYSHA GENE THERAPIES, INC. |
| 08/21/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in GRACELL BIOTECHNOLOGIES INC. |
| 08/17/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in NEKTAR THERAPEUTICS |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Bellus Health Inc. |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Kinnate Biopharma Inc. |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.7% stake in 89BIO, INC. |
| 08/09/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC. |
| 08/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.5% stake in TALARIS THERAPEUTICS, INC. |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in UNICYCIVE THERAPEUTICS, INC. |
| 06/12/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc. |
| 05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in TRAVERE THERAPEUTICS, INC. |
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DA32 Life Science Tech Acquisition Corp. |
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in ARYA SCIENCES ACQUISITION CORP V. |
| 04/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/27/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 5.2% stake in ENLIVEN THERAPEUTICS, INC. |
| 02/24/2023 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 7.8% stake in MINERALYS THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 1.3% stake in THIRD HARMONIC BIO, INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.9% stake in CELCUITY INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. has filed a Schedule 13D for Ascendis Pharma A/S |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in CONCERT PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.4% stake in GH Research PLC |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.7% stake in Kinnate Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in RHYTHM PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in ImmunoGen, Inc. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in 5:01 ACQUISITION CORP. |
|